Advertisement

BMC Cardiovascular Disorders

, 19:216 | Cite as

Infantile hepatic hemangiomas associated with high-output cardiac failure and pulmonary hypertension

  • Xin-tong Zhang
  • Wei-dong RenEmail author
  • Guang Song
  • Yang-jie Xiao
  • Fei-fei Sun
  • Nan Wang
Open Access
Case report
  • 57 Downloads
Part of the following topical collections:
  1. Hypertension and Cardiovascular Risk

Abstract

Background

Infantile hepatic hemangioma (IHH) is a rare endothelial cell neoplasm, which may be concurrent with severe complications and result in poor outcomes. Moreover, the coexistence of IHH and congenial heart disease is even rarer.

Case presentation

We present a 10-day-old male born with IHH associated with patent ductus arteriosus (PDA), atrial septal defect (ASD) and pulmonary hypertension. Moreover, we reviewed a series of studies of IHH-associated high-output cardiac failure between 1974 and 2018, and summarized the treatment outcomes.

Conclusions

Infantile hepatic hemangioma (IHH) has been known to induce high-output heart failure. There is no literature to summarize the severity of its impact on heart, which can lead to a high mortality rate. When IHH is detected by ultrasound, the heart should be evaluated to facilitate treatment. The outcomes of IHH associated with heart failure are good.

Keywords

Infantile hepatic hemangioma Pulmonary hypertension Congestive heart failure Congenital heart disease 

Abbreviations

ALT

Alanine aminotransferase

APTT

Activated partial thromboplastin time

ASD

Atrial septal defect

AST

Aspartate aminotransferase

BilD

Direct bilirubin

BilT

Total bilirubin

BNP

Brain natriuretic peptide

CHF

Congestive heart failure

CKMB

MB isoenzyme of creatine kinase

PTA

Prothrombin time activity

CT

Computed tomography

FIB

Fibrinogen

HGB

Hemoglobin

IHH

Infantile hepatic hemangioma

INR

International normalized ratio

MCH

Mean corpuscular hemoglobin

MRI

Magnetic resonance imaging

PDA

Patent ductus arteriosus

US

Ultrasonography

Background

Infantile hepatic hemangioma (IHH) is a rare proliferative endothelial cell tumor. It appears to be a benign tumor, however, it may lead to poor outcomes because of severe complications such as congestive heart failure (CHF), which occurs in 15% of infants with this disease [1]. More rarely, IHH is concurrent with congenital heart disease (CHD). Herein we present a patient with IHH, patent ductus arteriosus (PDA), and atrial septal defect (ASD). Meanwhile, we review and summarize the injury of IHH on the heart, and related outcomes.

Case presentation

A 10-day-old boy was born at 38 weeks’ gestation and had tachypnea at 65 breaths per minute. The liver margin was palpable 4 cm below the left costal margin. The heart rhythm was normal but a grade II-IV systolic murmur could be heard. Laboratory tests showed that his brain natriuretic peptide (BNP) level was greater than 5000 pg/ml. His CKMB was 110 U/L, C-reactive protein was 23.4 mg/L, alpha fetoprotein was greater than 1210 ng/ml, PTA 54%, INR 1.6, APTT 50 s, FIB 1.5 g/l, D-dimer 1064 μg/L, HGB, 123 g/L, MCH 36.4 pg, total bilirubin (BilT)196.7 umol/L, BilD 13.2 umol/L, ALT 44 U/L, and AST 23 U/L. Blood gas analysis revealed that the carbon dioxide pressure was raised to 53.4 mmHg and the oxygen partial pressure was 62.5 mmHg.

Echocardiography demonstrated a small PDA of 1.5-1.8 mm with right to left shunting, a large ASD with left to right shunting, and severe right atrial and right ventricular enlargement. A severe systolic pressure gradient of 70 mmHg suggested marked elevation of pulmonary artery pressure at the near systemic level. (Fig. 1) Color Doppler scanning of the liver displayed abundant blood flow in the lesion. (Fig. 2) The left hepatic vein was dilated to 8 mm with two great branches feeding the mass. (Fig. 3)The right hepatic artery and a branch arising from the abdominal aorta were also in close association with the lesion.
Fig. 1

IHH (Infantile hepatic hemangiomas) on abdominal ultrasound, in the left hepatic lobe. CDFI(Color doppler flow imaging) can be detected with abundant blood flow signals

Fig. 2

Views of the IHH from contrast-enhanced CT (Contrast-enhanced computed tomography). The left hepatic lobe is irregularly enhanced with a slightly lower density and the lesion shows peripheral enhancement of centripetal fill-in on arterial phase

Fig. 3

Expansion of the left hepatic vein close to the lesion

Contrast-enhanced computed tomography (CT) showed that the lesion enhanced irregularly in the left lobe of the liver. (Fig. 4)It was irregularly hypodense on plain scan with peripheral enhancement in the arterial phase and centripetal fill-in in the portal venous phase. In the delayed phases, the density of the leision was slightly higher than that of the liver parenchyma. The patient received diuretic therapy, fluid restriction, low-flow oxygen, and infection control for the management of the heart failure. After treatment his breathing difficulty improved. Then the patient was transferred to Beijing Children’s Hospital for surgery and the adhesion between the tumor and the intestine was found during the operation. The patient eventually died due to postoperative complications and multiple organ failure.
Fig. 4

View of the patient’s moderate to severe pulmonary arterial pressure

Discussion and conclusions

IHH is an endothelial cell neoplasm, a benign tumor, which is usually clinically silent and slowly progressive during childhood. Although almost all are asymptomatic, a small subset can produce high-output cardiac failure and cause considerable mortality. Its pathologic changes are similar to that of hepatic artery to hepatic vein or hepatic artery to portal vein arteriovenous fistula. The prognosis of the disease is poor when complications present and the mortality rate can be as high as 90% [2, 3]. We reviewed a series of recent studies of IHH-associated high-output cardiac failure between 1974 and 2018, and summarized the treatment outcomes.

Heart failure was obviously a clinical relevant complication in the 25 cases which were presented in Table 1 [2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22]. The age of diagnosis varied ranging from 1 day to 3.5 years. Eight patients (28%) presented with pulmonary hypertension including two mild, one moderate, three severe, and two unknown. Two of them were also associated with other congenital cardiac malformations which were illustrated in detail in Table 2 [7, 11, 13, 22, 23, 24]. Cardiac function improved after treatment in 15 patients, achieving normal value in 2. Consequently the outcomes of IHH-associated high-output cardiac failure proved to be quite satisfying. Most of the patients discharged or achieved remarkable improvement through appropriate treatment, while only 4 of them failed to survive.
Table 1

Summary of the literature on patients presenting with IHH associated with congestive heart failure

Study

Age

Sex

Cardiopathy

Diagnose

methods

Treatment

Cardiac recovery

Outcome

Mattioli et al. (1974) [16]

27d

F

BVH, PAH

HAG

Ligation

Normal

Discharged

Linderkamp et al. (1976) [14]

1d

M

CHF

Renal scan

Resection

Improve

Discharged

Rotman et al. (1980) [18]

4 m

F

CHF

VG

Glucocorticoid

Improve

Remarkable improvement

Burke et al. (1986) [2]

3.5y

F

Cardiomegaly

US,CT

Embolization

Failure

Gozal et al. (1990) [9]

17d

F

Cardiomegaly

US

Glucocorticoid

Improve

Discharged

Kristidis et al. (1991) [13]

3d

M

ASD,BVH,PDA

US

Prednisone

Improve

Discharged

3d

M

CHF

US

Prednisone,digoxin

Improve

Discharged

1d

F

CHF

US

Prednisone

Improve

Discharged

Barsever et al. (1994) [4]

2w

F

CHF cardiomegaly

US,CT

Interferon

Remarkable improvement

Hazebroek et al. (1995) [10]

2d

M

CHF

US,HAG

Ligation

Improve

Remarkable improvement

Fok et al. (1996) [8]

1d

M

CR = 0.77, CHF

US,TRA

Embolization

Discharged

Lu C C et al. (2002) [15]

1d

F

CR = 0.8

US,CT

Glucocorticoid,dopamine

------------

Remarkable improvement

10d

M

BVH

US,MRI

Ligation

Improve

Discharged

Sakamoto et al. (2010) [19]

4d

F

CHF

CT

Transplantation

Remarkable improvement

Mhanna et al. (2011) [17]

8w

F

CHF

US,CT

Glucocorticoid,propranolol

------------

Discharged

 

3 m

M

ASD,CHF,LVH,PDA

US

Glucocorticoid,propranolol

------------

Discharged

Dotan et al. (2013) [7]

11w

F

BVH,PAH

US

propranolol

Improve

Discharged

Dasgupta et al. (2013) [6]

1d

M

BVH

US,CT

Glucocorticoid

Improve

Remarkable improvement

Chopra et al. (2014) [5]

9 m

F

CHF

US,CT

Glucocorticoid

Failure

Ye et al. (2014) [14]

59d

F

PAH,RVH

US,MRI

Surgery

Failure

Imai et al. (2015) [12]

1d

M

Cardiomegaly

MRI,CT

Glucocorticoid

Improve

Discharged

Wang et al. (2015) [24]

5 m

F

Cardiomegaly,PA

US,CT

Embolization

Improve

Discharged Failure

19d

F

H BVH,PAH

US,CT

Embolization

Improve

 

Shen et al. (2016) [20]

11d

M

CHF

US

Glucocorticoid, Embolization

Normal

Discharged

Hutchins et al. (2017) [11]

22 m

F

VSD

US,CT,MRI

Glucocorticoid,Sirolimus

Discharged

BVH Biventricular hypertrophy, RVH Right ventricular hypertrophy, “——“ No information available, CR Cardiothoracic ratio, VG Venacavography, HAG Hepatic arterograph

Table 2

Summary of patients presenting with IHH associated with pulmonary artery hypertension

Study

Sex

Age

EF(%)

Heart

TR

PAH mmHG

PDA

VSD,ASD

Present study

M

10d

72

RHE

moderate

70

1.5-1.8 mm

R-L

ASD 7.5 mm L-R

Wang et al. (2015) [24]

F

5 m

78

cardiomegaly

54

Kristidis et al. (1991) [13]

F

19d 3d

64

RHE cardiomegaly

severe

90 PAH

--

--

F

 

--

 

--

 

--

Small ASD L-R

Dotan et al. (2013) [7]

F

11w

normal

BVH

mild to moderate

58

Ye et al. (2014) [22]

F

59d

RHE

120

Ersch et al. (2002) [23]

F

20 m

RHE

PAH

Hutchins et al. (2017) [11]

F

22 m

RHE

mild to moderate

70

Small VSD

RHE Right heart enlargement, BVH Biventricular hypertrophy, PDA Patent ductus arteriosus, R-L Right to left shunt, L-R Left to right shunt, TR Tricuspid regurgitation, −- No information available

IHH can be classified as focal, multifocal, or diffuse [9]. The diagnosis of IHH relies on ultrasonography (US), CT, and magnetic resonance imaging (MRI). CT and MRI can reveal discrete lesions in patients. Diffuse lesions require baseline determination of size, cardiac and thyroid function, and coagulation profile. When IHH is associated with heart disease, cardiac structure and function can be observed by echocardiography, which can identify intra- or extracardiac disease [3]. There were 13 (52%) patients in our series that were diagnosed by echocardiography. In our case, the patient had a focal lesion, which is diagnosed primarily by ultrasonography and CT.

The pathological mechanism of CHF in IHH is associated with arteriovenous shunts in hemangiomas. The arteriovenous shunts result in a decrease of systemic blood volume as well as increase of pulmonary blood volume, thus leading to the cardiac output increase. Furthermore, aggravated by the pulmonary hypertention it finally leads to high-output CHF [21]. In fetal stage, high pulmonary vascular resistance and pulmonary pressure help maintain the fetal circulation, however, after birth the high pulmonary pressure will descend gradually within 3 months while systemic pressure of neonates will ascend with closure of oral foramen. Nevertheless, the existence of IHH can increase the load of right heart system and affect circulation transition from fetus to neonate, which further increase pulmonary vascular resistance and cause pulmonary hypertention.

Various therapies have been reported to treat IHH, including drugs, embolization, ligation, and resection [25]. (1) Drugs: steroid therapy functioned well in improving hemodynamics, reducing hepatic vascularity as well as deferring early emergency delivery in congestive heart failure fetus as recorded in literatures. There are no significant differences between single or combined drug use in the literature. (2) Embolization: embolization has been strongly suggested for provisional stabilization of fatal congestive heart failure combined with pharmacological therapy. (3) Ligation: ligation can reduce oxygen supply to hepatocytes and improve liver function. (4) Resection: surgery should be considered when medical management failed [3].Treatment methods and their outcomes as described in the literature are shown in Table 3. Among 25 patients, four ended in treatment failure (18%).
Table 3

Demographics for treatment outcomes

IHH

All

Success

Failure

Embolization

5

3

2

Ligation

3

3

0

Resection

1

1

0

Transplantation

1

1

1

Drugs:

10

9

1

Glucocorticoid propranolol

2

2

0

Glucocorticoid dopamine

1

1

0

Prednisone digoxin

1

1

0

Glucocorticoid

5

4

1

Propranolol

1

1

0

Prednisone

2

2

0

Interferon

1

1

0

Glucocorticoid,Sirolimus

1

1

0

25

21

4

Success = remarkable improvement or discharged

Early age of onset is typical of IHH with heart failure. When IHH is detected by US, echocardiography should also be performed timely for more detailed information about cardiac structure and function. For infants in life-threatening and complicated conditions, US and echocardiography should be performed as early as possible to evaluate IHH associated with congestive heart failure and to facilitate treatment therapies. With regard to the treatment in our review, outcomes of IHH with heart failure are considered to be good.

Notes

Acknowledgements

We thank Dr. Ying Ren for the computed tomography image acquisition.

Authors’ contributions

F-FS and NW performed echocardiographic examination and collected the images. Y-JX and GS participated in the design of the study and performed data analysis. W-DR revised critically for important intellectual content before manuscript submitted. X-TZ drafted the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by grants from National natural Science Foundation of China (81571686 to W.D.R) and National natural Science Foundation of Liaoning (2018053064 to F.F.S). The funding bodies assisted in the collection of clinical datas and publication fees.

Ethics approval and consent to participate

The study has been approved by the ethics committee of Shengjing Hospital of China Medical University, Shenyang, China.

Consent for publication

Written informed consent was obtained from the parents of the patient for publication of this case report and any identifying images.

Competing interests

The authors declare that they have no competing interests.

References

  1. 1.
    Selby DM, Stocker JT, Waclawiw MA, Hitchcock CL, Ishak KG. Infantile hemangioendothelioma of the liver. Hepatology. 2010;20(1):39–45.Google Scholar
  2. 2.
    Burke DR, Verstandig A, Edwards O, Meranze SG, McLean GK, Stein EJ. Infantile hemangioendothelioma: angiographic features and factors determining efficacy of hepatic artery embolization. Cardiovasc Intervent Radiol. 1986;9(3):154–7.CrossRefGoogle Scholar
  3. 3.
    Samuel M, Spitz L. Infantile hepatic hemangioendothelioma: the role of surgery. J Pediatr Surg. 1995;30(10):1425–9.CrossRefGoogle Scholar
  4. 4.
    Bar-Sever Z, Horev G, Lubin E, Kornreich L, Naor N, Ziv N, Shimoni A, Grunebaum M. A rare coexistence of a multicentric hepatic hemangioendothelioma with a large brain hemangioma in a preterm infant. Pediatr Radiol. 1994;24(2):141–2.CrossRefGoogle Scholar
  5. 5.
    Chopra R, Arora P, Yadav RK. Diagnosis of infantile hemangioendothelioma of the liver by triple phase computed tomography. Int J Contemp Pediatrics. 2014;1(3):184-6.Google Scholar
  6. 6.
    Dasgupta MK, Das S, Patra C, Sarkar S. Symptomatic infantile hepatic hemangioendothelioma successfully treated with steroid. J Clin Neonatol. 2013;2(4):187–9.CrossRefGoogle Scholar
  7. 7.
    Dotan M, Lorber A. Congestive heart failure with diffuse neonatal hemangiomatosis--case report and literature review. Acta Paediatr. 2013;102(5):e232.CrossRefGoogle Scholar
  8. 8.
    Fok TF, Chan MS, Metreweli C, Ng PC, Yeung CK, Li AK. Hepatic haemangioendothelioma presenting with early heart failure in a newborn: treatment with hepatic artery embolization and interferon. Acta Paediatr. 1996;85(11):1373–5.CrossRefGoogle Scholar
  9. 9.
    Gozal D, Saad N, Bader D, Berger A, Jaffe M. Diffuse neonatal haemangiomatosis: successful management with high dose corticosteroids. Eur J Pediatr. 1990;149(5):321–4.CrossRefGoogle Scholar
  10. 10.
    Hazebroek FW, Tibboel D, Robben SG, Bergmeyer JH, Molenaar JC. Hepatic artery ligation for hepatic vascular tumors with arteriovenous and arterioportal venous shunts in the newborn: successful management of two cases and review of the literature. J Pediatr Surg. 1995;30(8):1127–30.CrossRefGoogle Scholar
  11. 11.
    Hutchins KK, Ross RD, Kobayashi D, Martin A, Rajpurkar M. Treatment of refractory infantile hemangiomas and pulmonary hypertension with Sirolimus in a pediatric patient. J Pediatr Hematol Oncol. 2017;39(7):e391–3.CrossRefGoogle Scholar
  12. 12.
    Imai H, Hidaka N, Murakami T, Kido S, Yumoto Y, Fukushima K, Kato K. In utero sonographic findings of Giant hepatic hemangioma and associated perinatal complications: a report of two cases. J Med Ultrasound. 2015;23(1):46–51.CrossRefGoogle Scholar
  13. 13.
    Kristidis P, de Silva M, Howman-Giles R, Gaskin KJ. Infantile hepatic haemangioma: investigation and treatment. J Paediatr Child Health. 1991;27(1):57–61.CrossRefGoogle Scholar
  14. 14.
    Linderkamp O, Hopner F, Klose H, Riegel K, Hecker WC. Solitary hepatic hemangioma in a newborn infant complicated by cardiac failure, consumption coagulopathy, microangiopathic hemolytic anemia, and obstructive jaundice. Case report and review of the literature. Eur J Pediatr. 1976;124(1):23–9.CrossRefGoogle Scholar
  15. 15.
    Lu CC, Ko SF, Liang CD, Kuo HW, Tiao MM. Infantile hepatic hemangioendothelioma presenting as early heart failure: report of two cases. Chang Gung Med J. 2002;25(6):405–10.PubMedGoogle Scholar
  16. 16.
    Mattioli L, Lee KR, Holder TM. Hepatic artery ligation for cardiac failure due to hepatic hemangioma in the newborn. J Pediatr Surg. 1974;9(6):859–62.CrossRefGoogle Scholar
  17. 17.
    Mhanna A, Franklin WH, Mancini AJ. Hepatic infantile hemangiomas treated with oral propranolol--a case series. Pediatr Dermatol. 2011;28(1):39–45.CrossRefGoogle Scholar
  18. 18.
    Rotman M, John M, Stowe S, Inamdar S. Radiation treatment of pediatric hepatic hemangiomatosis and coexisting cardiac failure. N Engl J Med. 1980;302(15):852.CrossRefGoogle Scholar
  19. 19.
    Sakamoto S, Kasahara M, Shigeta T, Fukuda A, Kakiuchi T, Miyasaka M, Nosaka S, Nakano N, Nakagawa A, Horikawa R. Living donor liver transplantation for multiple intrahepatic portosystemic shunts after involution of infantile hepatic hemangiomas. J Pediatr Surg. 2011;46(6):1288–91.CrossRefGoogle Scholar
  20. 20.
    Shen WC, Liang PC, Wu JF, Hsu CT, Chen HS, Chen HL. Combined Transarterial embolization and propranolol as effective treatment for hepatic hemangioma with Kasabach-Merritt syndrome and heart failure in a neonate. Pediatr Neonatol. 2017;58(2):191–3.CrossRefGoogle Scholar
  21. 21.
    Wang T, Wang Y, Liang Y, Lu G. Infantile hepatic Hemangioendothelioma associated W’ith congestive heart failure: two case reports with different outcomes. Medicine (Baltimore). 2015;94(52):e2344.CrossRefGoogle Scholar
  22. 22.
    Ye JJ, Shao YC, Shu Q. Imaging findings of multiple infantile hepatic hemangioma associated with cardiac insufficiency. World J Pediatr. 2014;10(4):368–70.CrossRefGoogle Scholar
  23. 23.
    Ersch J, Banziger O, Braegger C, Arbenz U, Stallmach T. An infant with pulmonary hypertension due to a congenital Porto-caval shunt. Eur J Pediatr. 2002;161(12):660–2.CrossRefGoogle Scholar
  24. 24.
    Wang T, Wang Y, Liang Y, Lu G. Infantile hepatic Hemangioendothelioma associated with congestive heart failure: two case reports with different outcomes. Medicine (Baltimore). 2015;94(52):e2344.CrossRefGoogle Scholar
  25. 25.
    Ozyer U, Kirbas I, Aytekin C, Hasdogan B. Coil embolization of a congenital intrahepatic arterioportal fistula: increasing experience in management. Pediatr Radiol. 2008;38(11):1253–6.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of UltrasoundShengjing Hospital of China Medical UniversityShenyangChina

Personalised recommendations